Trump to visit Fed on Thursday amid Powell feud, renovation probe
H.C. Wainwright maintained its buy rating and $40 price target on Kura Oncology (NASDAQ:KURA), significantly above the current trading price of $6.66, following updated clinical trial results presented at the European Hematology Association meeting. According to InvestingPro data, analysts remain bullish with a consensus "Strong Buy" recommendation, despite the stock’s 69% decline over the past year.
The firm highlighted new data from the Phase 1a/1b KOMET-007 trial evaluating ziftomenib in combination with standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients with specific genetic mutations. The trial included 82 patients, with 49 having NPM1 mutations and 33 with KMT2A rearrangements. InvestingPro analysis shows Kura maintains a strong financial position with more cash than debt and a healthy current ratio of 8.07x.
Results demonstrated ziftomenib’s favorable safety profile when combined with cytarabine/daunorubicin (7+3) chemotherapy regimen. The data showed high rates of composite complete response and minimal residual disease negativity, with no dose-limiting toxicities and minimal QTc prolongation or differentiation syndrome events.
H.C. Wainwright noted that these findings suggest potential for ziftomenib as an early intervention in the first-line setting for AML patients. The firm expressed optimism about ziftomenib’s emerging profile as both a monotherapy and combination treatment.
Kura Oncology plans to initiate pivotal Phase 3 trials (KOMET-017-IC and KOMET-017-NIC) in newly diagnosed patients during the second half of 2025, while additional results from ziftomenib combined with venetoclax/azacitidine in relapsed/refractory AML are anticipated in the same timeframe. Based on InvestingPro’s Fair Value analysis, the stock appears undervalued at current levels. Discover 10+ additional exclusive insights and detailed financial analysis available in the Pro Research Report.
In other recent news, Kura Oncology announced promising results from the Phase 2 KOMET-001 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluated ziftomenib for relapsed or refractory NPM1-mutant acute myeloid leukemia, showing a 23% complete remission rate and a 63% minimal residual disease-negative rate. The U.S. Food and Drug Administration has accepted the New Drug Application for ziftomenib, granting it priority review with a Prescription Drug User Fee Act date set for November 30, 2025. Kura Oncology is preparing to initiate frontline trials in the second half of 2025, supported by a pro forma cash position of $703.2 million. Citizens JMP, Leerink Partners, and Cantor Fitzgerald have all reiterated positive ratings for Kura Oncology, highlighting the company’s strategic progress. The KOMET-007 trial also demonstrated a 92% complete remission composite rate in first-line acute myeloid leukemia treatment. Kura’s financial standing and trial results position the company for potential regulatory approval and market presence. The company plans to host an investor event to discuss these developments and future milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.